Cargando…
Complement Regulatory Genetic Mutations in the Setting of Autoimmune Thrombotic Thrombocytopenic Purpura: A Case Series
OBJECTIVE: To explore the benefits of adding eculizumab for the treatment of refractory autoimmune thrombotic thrombocytopenic purpura (iTTP) with complement dysregulation. PATIENTS AND METHODS: From January 1, 2014, through July 1, 2017, we identified patients with iTTP defined by ADAMTS13 (disinte...
Autores principales: | Atrash, Shebli, Sasapu, Appalanaidu, Pandey, Soumya, Cottler-Fox, Michele, Motwani, Pooja |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6124327/ https://www.ncbi.nlm.nih.gov/pubmed/30225434 http://dx.doi.org/10.1016/j.mayocpiqo.2017.11.004 |
Ejemplares similares
-
Complement and cytokine response in acute Thrombotic Thrombocytopenic Purpura
por: Westwood, John-Paul, et al.
Publicado: (2014) -
Thrombotic thrombocytopenic purpura
por: Knöbl, Paul
Publicado: (2018) -
Complement Inhibition in the Treatment of SLE-Associated Thrombotic Thrombocytopenic Purpura
por: Boneparth, Alexis, et al.
Publicado: (2015) -
Chronic Lymphocytic Leukemia with Translocation (2;14)(p16;q32): A Case Report and Review of the Literature
por: Socola, Francisco, et al.
Publicado: (2016) -
Caplacizumab use for immune thrombotic thrombocytopenic purpura: the Milan thrombotic thrombocytopenic purpura registry
por: Agosti, Pasquale, et al.
Publicado: (2023)